Oxidant/Antioxidant Status in Patients with Negative Myeloproliferative Neoplasms.

Excessive production of reactive oxygen species (ROS) leading to oxidative stress have been associated with many leukemias. In order to show whether there is a difference in ROS levels and total antioxidant power between negative myeloproliferative neoplasms (MPNs) patients and controls, this study aims to evaluate the oxidant/antioxidant status in patients with MPN. 43 subjects with negative MPNs and 40 healthy controls were included in this study. Oxidative stress was investigated by determination of total antioxidant power, catalase activity and concentrations of vitamins (A, C and E), malondialdehyde, hydroperoxides and carbonylated proteins. Oxygen Radical Absorbance Capacity (ORAC) was lower in negative MPN patients compared with control group (0.40 ± 0.17 vs. 0.81 ± 0.06) AU (p˂0.01). Vitamins A (0.61 ± 0.19 vs. 0.82 ± 0.11) mol/L (p˂0.05), E (0.29 ± 0.08 vs. 1.10 ± 0.56) mol/L (p˂0.01) and C (19.22 ± 0,49 vs. 45.52 ± 0.36)µg/mL (p˂0.01) concentrations were lower in the same group compared to controls. No difference in catalase (CAT) activity between the negative MPN and control groups was observed ( > 0.05). Higher malondialdehyde (MDA) plasma levels were found in negative MPN patients compared to controls (2.97 ± 0.24 vs. 0.38 ± 0.18) mmol/L ( < 0.01). No significant differences were observed between negative MPN and control groups in plasma hydroperoxide and carbonyl protein rates ( > 0.05;  > 0.05). negative myeloproferative neoplasms are associated with dysregulation of redox balance of oxidant /antioxidant leading to an oxidative stress status.